Nurix Therapeutics, Inc.
NRIX
$9.63
$0.101.05%
NASDAQ
| 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 264.34% | 11.26% | -12.37% | -31.84% | -60.58% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 264.34% | 11.26% | -12.37% | -31.84% | -60.58% |
| Cost of Revenue | 59.63% | 39.31% | 35.22% | 15.93% | 6.90% |
| Gross Profit | 7.58% | -53.23% | -56.10% | -45.95% | -144.12% |
| SG&A Expenses | 21.96% | -1.23% | -0.58% | 10.31% | 0.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 52.36% | 31.57% | 28.84% | 14.91% | 5.56% |
| Operating Income | 0.45% | -39.02% | -42.62% | -36.49% | -81.36% |
| Income Before Tax | 3.94% | -36.02% | -39.53% | -32.16% | -83.12% |
| Income Tax Expenses | 744.44% | -- | -- | -- | -- |
| Earnings from Continuing Operations | 2.43% | -35.73% | -39.55% | -32.38% | -83.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.43% | -35.73% | -39.55% | -32.38% | -83.49% |
| EBIT | 0.45% | -39.02% | -42.62% | -36.49% | -81.36% |
| EBITDA | 0.28% | -40.16% | -41.54% | -37.19% | -85.81% |
| EPS Basic | 27.43% | 10.82% | 2.70% | 1.06% | -59.61% |
| Normalized Basic EPS | 28.56% | 10.62% | 2.71% | 1.25% | -59.30% |
| EPS Diluted | 27.43% | 10.82% | 2.70% | 1.06% | -59.61% |
| Normalized Diluted EPS | 28.56% | 10.62% | 2.71% | 1.25% | -59.30% |
| Average Basic Shares Outstanding | 34.48% | 52.20% | 43.42% | 33.81% | 14.96% |
| Average Diluted Shares Outstanding | 34.48% | 52.20% | 43.42% | 33.81% | 14.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |